AR090491A1 - Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo - Google Patents
Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetiloInfo
- Publication number
- AR090491A1 AR090491A1 ARP130100966A AR090491A1 AR 090491 A1 AR090491 A1 AR 090491A1 AR P130100966 A ARP130100966 A AR P130100966A AR 090491 A1 AR090491 A1 AR 090491A1
- Authority
- AR
- Argentina
- Prior art keywords
- laquinimod
- treatment
- combination
- multiple sclerosis
- fumarate
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 229960004577 laquinimod Drugs 0.000 title abstract 3
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 4
- 229960004419 dimethyl fumarate Drugs 0.000 abstract 4
- 206010071068 Clinically isolated syndrome Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Exchange Systems With Centralized Control (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616337P | 2012-03-27 | 2012-03-27 | |
| US13/800,047 US20130259856A1 (en) | 2012-03-27 | 2013-03-13 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090491A1 true AR090491A1 (es) | 2014-11-19 |
Family
ID=49235339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100966 AR090491A1 (es) | 2012-03-27 | 2013-03-25 | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20130259856A1 (enExample) |
| EP (1) | EP2830623A4 (enExample) |
| JP (2) | JP2015512406A (enExample) |
| KR (1) | KR20150003765A (enExample) |
| CN (2) | CN104470520A (enExample) |
| AR (1) | AR090491A1 (enExample) |
| AU (2) | AU2013239850A1 (enExample) |
| CA (1) | CA2868259A1 (enExample) |
| EA (1) | EA201491773A1 (enExample) |
| HK (1) | HK1205941A1 (enExample) |
| IL (1) | IL234687A0 (enExample) |
| MX (1) | MX2014011616A (enExample) |
| SG (2) | SG10201607976WA (enExample) |
| TW (1) | TW201343164A (enExample) |
| UY (1) | UY34720A (enExample) |
| WO (1) | WO2013148690A1 (enExample) |
| ZA (1) | ZA201407722B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| US20140348915A9 (en) | 2012-08-22 | 2014-11-27 | Xenoport, Inc. | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| EP2970129A2 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途 |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| EP3110408B1 (en) | 2014-02-28 | 2019-01-16 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| KR20170005434A (ko) | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
| DK3256125T3 (da) | 2014-12-11 | 2022-03-21 | Actelion Pharmaceuticals Ltd | Doseringsregimen for ponesimod, en selektiv s1p1-receptoragonist |
| MA41139B1 (fr) | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
| WO2017120355A1 (en) * | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| US12483171B2 (en) | 2023-12-18 | 2025-11-25 | Abb Schweiz Ag | Plug and play solid state controller for high efficiency motors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US20100144651A1 (en) * | 2005-07-07 | 2010-06-10 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use |
| SG10201508623RA (en) | 2005-10-19 | 2015-11-27 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR20150065951A (ko) | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| DK2653873T3 (da) | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| PT2139467T (pt) * | 2007-02-08 | 2016-12-16 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
| EP2442651B1 (en) * | 2009-06-19 | 2015-07-29 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| PT2533634E (pt) * | 2010-02-12 | 2015-12-28 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| RU2603047C2 (ru) * | 2011-01-25 | 2016-11-20 | Новартис Аг | Система и способы для медицинского использования отображения и захвата движения |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
-
2013
- 2013-03-13 US US13/800,047 patent/US20130259856A1/en not_active Abandoned
- 2013-03-25 AR ARP130100966 patent/AR090491A1/es unknown
- 2013-03-25 TW TW102110549A patent/TW201343164A/zh unknown
- 2013-03-26 JP JP2015503465A patent/JP2015512406A/ja not_active Withdrawn
- 2013-03-26 HK HK15106555.7A patent/HK1205941A1/xx unknown
- 2013-03-26 SG SG10201607976WA patent/SG10201607976WA/en unknown
- 2013-03-26 EA EA201491773A patent/EA201491773A1/ru unknown
- 2013-03-26 KR KR20147030064A patent/KR20150003765A/ko not_active Withdrawn
- 2013-03-26 CN CN201380016933.3A patent/CN104470520A/zh active Pending
- 2013-03-26 SG SG11201405755QA patent/SG11201405755QA/en unknown
- 2013-03-26 CN CN201610252021.1A patent/CN105853422A/zh active Pending
- 2013-03-26 EP EP13768294.4A patent/EP2830623A4/en not_active Withdrawn
- 2013-03-26 AU AU2013239850A patent/AU2013239850A1/en not_active Abandoned
- 2013-03-26 CA CA 2868259 patent/CA2868259A1/en not_active Abandoned
- 2013-03-26 MX MX2014011616A patent/MX2014011616A/es unknown
- 2013-03-26 WO PCT/US2013/033885 patent/WO2013148690A1/en not_active Ceased
- 2013-04-02 UY UY34720A patent/UY34720A/es not_active Application Discontinuation
-
2014
- 2014-09-16 IL IL234687A patent/IL234687A0/en unknown
- 2014-10-23 ZA ZA2014/07722A patent/ZA201407722B/en unknown
-
2015
- 2015-01-05 US US14/589,684 patent/US20150119420A1/en not_active Abandoned
- 2015-09-14 US US14/853,826 patent/US20160000774A1/en not_active Abandoned
-
2017
- 2017-04-24 US US15/495,406 patent/US20170224675A1/en not_active Abandoned
- 2017-05-26 JP JP2017104051A patent/JP2017200927A/ja not_active Withdrawn
- 2017-07-27 US US15/662,165 patent/US20170319570A1/en not_active Abandoned
- 2017-11-03 US US15/803,017 patent/US20180050031A1/en not_active Abandoned
-
2018
- 2018-01-04 AU AU2018200065A patent/AU2018200065A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2830623A4 (en) | 2015-09-02 |
| US20150119420A1 (en) | 2015-04-30 |
| HK1205941A1 (en) | 2015-12-31 |
| KR20150003765A (ko) | 2015-01-09 |
| IL234687A0 (en) | 2014-11-30 |
| CN105853422A (zh) | 2016-08-17 |
| JP2015512406A (ja) | 2015-04-27 |
| WO2013148690A1 (en) | 2013-10-03 |
| TW201343164A (zh) | 2013-11-01 |
| AU2018200065A1 (en) | 2018-02-01 |
| SG10201607976WA (en) | 2016-11-29 |
| UY34720A (es) | 2013-10-31 |
| ZA201407722B (en) | 2016-06-29 |
| JP2017200927A (ja) | 2017-11-09 |
| EP2830623A1 (en) | 2015-02-04 |
| SG11201405755QA (en) | 2014-10-30 |
| EA201491773A1 (ru) | 2015-02-27 |
| US20130259856A1 (en) | 2013-10-03 |
| CN104470520A (zh) | 2015-03-25 |
| AU2013239850A1 (en) | 2014-11-06 |
| CA2868259A1 (en) | 2013-10-03 |
| MX2014011616A (es) | 2014-10-17 |
| US20170319570A1 (en) | 2017-11-09 |
| US20180050031A1 (en) | 2018-02-22 |
| US20160000774A1 (en) | 2016-01-07 |
| US20170224675A1 (en) | 2017-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| IN2014MN00333A (enExample) | ||
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
| WO2015165413A8 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| CL2012000319A1 (es) | Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. | |
| MX366090B (es) | Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. | |
| UY34775A (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| NZ726132A (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| IN2014DN09240A (enExample) | ||
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| AR097179A1 (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y flupirtina | |
| CO7170180A2 (es) | Composición farmacéutica inyectable de dexketoprofeno y tramadol | |
| UY35748A (es) | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple | |
| AR088093A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y acetato de glatiramer | |
| PH12014500252A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| HK1227691A1 (zh) | 利用拉喹莫德和特立氟胺的组合来治疗多发性硬化症 | |
| PL2852400T3 (pl) | Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |